Portola Pharmaceuticals, Inc. has received $-1.1 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-1.34 while the top line estimate is $-0.87 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 10.57%.
Portola Pharmaceuticals, Inc. results fell short with a surprise EPS of -51.85% or $-0.56. The Actual EPS was $-1.64 compared to the Estimated EPS of $-1.08 during its most recent quarterly earnings.
In the last quarter, Portola Pharmaceuticals, Inc. reported Annual Earnings of $-1.64. Based on the filings, last years Annual Earnings was, $-4.36. In the last Quarter, PTLA reported a surprise Earnings per Share of -51.85% . The consensus estimate for current quarter is $-1.1 and for the current fiscal year, the estimate is $-4.92. For the Next fiscal year, the estimate is $-4.26 based on the consensus.
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) : On Tuesday heightened volatility was witnessed in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) which led to swings in the share price. The stock opened for trading at $25.22 and hit $27.8 on the upside , eventually ending the session at $27.25, with a gain of 6.7% or 1.71 points. The heightened volatility saw the trading volume jump to 1,278,759 shares. The 52-week high of the share price is $35.32 and the company has a market cap of $1,541 million. The 52-week low of the share price is at $15.68 .
Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.